GlassScriptPhysician profile
Tran Le
NPI 1265937775
$4,902.64
in general payments reported to CMS, 2019-2025
20 companies · $2,559 in 2025
The $2,559 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $325 · 2024: $1,897 · 2025: $2,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,780.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,132.99 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $598.28 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $549.20 | 2024-2025 | |
| Amgen INC. | $445.28 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $445.13 | 2024-2025 | |
| Novo Nordisk INC | $392.39 | 2024-2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $254.49 | 2024-2025 | Gemtesa |
| Gilead Sciences, INC. | $243.70 | 2022-2023 | |
| Lilly USA, LLC | $200.45 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $172.82 | 2025 | Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.39 | 2024-2025 | Jardiance |
| Scilex Pharmaceuticals INC. | $75.84 | 2024 | |
| Exact Sciences Corporation | $67.30 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $46.17 | 2024 | |
| Ardelyx, INC. | $39.62 | 2025 | Ibsrela |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $25.75 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $24.05 | 2024 | Rexulti |
| Agios Pharmaceuticals, INC. | $22.29 | 2025 | Pyrukynd |
| Corcept Therapeutics | $19.32 | 2025 | Korlym |
| Hologic Sales and Service, LLC | $16.18 | 2024 | Aptima, Thinprep 2000 Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tran Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.